Emerging Therapeutic Strategies in High-Risk Smoldering Multiple Myeloma

This opening segment sets the stage for the discussion by framing the evolving treatment landscape in high-risk smoldering multiple myeloma. Faculty introduce the historical context in which SMM has traditionally been managed with observation alone and outline why recent advances have renewed interest in earlier therapeutic intervention for select patients.

The conversation highlights the clinical rationale for reassessing a watch-and-wait approach in high-risk disease, including the substantial risk of early progression to symptomatic multiple myeloma and the potential consequences of delayed treatment. Panelists discuss how emerging evidence, culminating in the AQUILA phase 3 trial and subsequent FDA approval of subcutaneous daratumumab, represents a pivotal shift in the management paradigm for this population.

This segment establishes the foundational themes for the program, including risk stratification, timing of intervention, and the balance between delaying disease progression and preserving quality of life in asymptomatic patients, providing context for the data and clinical perspectives explored in subsequent segments.